Clinical and Immunologic Predictors of Mycobacterium avium Complex Immune Reconstitution Inflammatory Syndrome in a Contemporary Cohort of Patients With Human Immunodeficiency Virus

Abstract Background People with human immunodeficiency virus (HIV) can present with new or worsening symptoms associated with Mycobacterium avium complex (MAC) infection shortly after antiretroviral therapy (ART) initiation as MAC immune reconstitution inflammatory syndrome (MAC-IRIS). In this study...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2021-06, Vol.223 (12), p.2124-2135
Main Authors: Breglio, Kimberly F, Vinhaes, Caian L, Arriaga, María B, Nason, Martha, Roby, Gregg, Adelsberger, Joseph, Andrade, Bruno B, Sheikh, Virginia, Sereti, Irini
Format: Article
Language:English
Subjects:
Alkaline phosphatase
Anti-HIV Agents
Antiretroviral drugs
Antiretroviral therapy
Bacterial infections
Body mass index
CD38 antigen
CD4 antigen
CD8 antigen
Cell activation
Hemoglobin
HIV
HIV Infections - complications
HIV Infections - drug therapy
Human immunodeficiency virus
Humans
Immune reconstitution
Immune Reconstitution Inflammatory Syndrome
Immune system
Inflammation
Lymphocytes T
Major and Brief Reports
Mycobacterium avium
Mycobacterium avium Complex
Mycobacterium avium-intracellulare Infection
Patients
Prospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background People with human immunodeficiency virus (HIV) can present with new or worsening symptoms associated with Mycobacterium avium complex (MAC) infection shortly after antiretroviral therapy (ART) initiation as MAC immune reconstitution inflammatory syndrome (MAC-IRIS). In this study, we assessed the utility of several laboratory tests as predictors of MAC-IRIS. Methods People with HIV with clinical and histologic and/or microbiologic evidence of MAC-IRIS were identified and followed up to 96 weeks post–ART initiation within a prospective study of 206 ART-naive patients with CD4
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiaa669